Adherium Outlines Commercial Progress and Value-Based Care Strategy

Adherium (ASX: ADR) has outlined its progress from a connected-device developer towards a commercial respiratory care business built around recurring patient revenue and longer-term outcomes contracts.

Remote patient monitoring (RPM) subscription revenue increased about 9.4 times over the 12 months to June 2026, while 5,300 devices were shipped by 30 June—ahead of guidance for approximately 5,000.

The Hailie Platform had more than 2,600 active RPM patients and is targeting around 10,000 patients by the end of calendar 2026, with reimbursement of about US$55 per patient per month under established RPM and remote therapeutic monitoring codes.

Adherium’s strategy is to continue scaling its reimbursed patient base while using clinical evidence and existing infrastructure to pursue potentially higher-margin value-based care (VBC) contracts.

Building a Recurring Platform

The Hailie platform combines connected devices, patient engagement tools, clinical care management, healthcare provider decision support, and real-time data to monitor medication adherence and inhaler technique between clinic visits.

The US Food and Drug Administration and Australia’s Therapeutic Goods Administration have cleared 12 of Adherium’s devices, which span metered dose inhalers (MDIs) and dry powder inhalers (DPIs) and generate about 24 objective signals per patient each day.

Quarterly RPM subscription revenue rose from $51,000 in the June 2025 quarter to an estimated $479,000 in the June 2026 quarter, with intervening quarterly revenue of $92,000, $171,000, and $344,000.

The business has expanded its leadership capability across commercial development, finance, product, clinical affairs and VBC as it moves beyond device supply towards broader respiratory care delivery.

Growing Clinical Evidence

The independent iCARE Quality Improvement Program at Intermountain Health reported a 57% reduction in total cost of care from US$36,837 to US$15,899 per patient per year, alongside 50% fewer hospital admissions and 20% fewer emergency department visits.

The program generated more than 12 million data points through connected devices, wearables and patient-reported information, feeding a behavioural AI platform and pulmonary disease navigators so emerging risks could be addressed more quickly.

Patient retention reached 92% at 12 months and 89.4% at 18 months among 1,049 patients, while Adherium expects further clinical and economic data releases over the next six to nine months.

Adherium has refined enrolment towards moderate-to-severe asthma and chronic obstructive pulmonary disease patients after recent attrition was concentrated among mild, reliever-only asthma patients with lower perceived need.

Managing Larger Cohorts

The current RPM model earns recurring revenue by enrolling and managing individual patients, while VBC would use the same platform to manage larger cohorts by exception and potentially capture a share of healthcare savings.

Multiple national payers are undertaking confidential evaluations of the respiratory program, with finance, pharmacy, and medical teams modelling potential savings through the committee processes that typically precede contracts.

Adherium is targeting continued RPM revenue growth and onboarding optimisation in the first quarter of the 2027 financial year, followed by a first VBC pilot or contract in the second quarter.

Shared-savings revenue from an initial VBC arrangement is targeted for the second or third quarter of the 2028 financial year, alongside monetisation of the risk-model and algorithm layer built on Adherium’s proprietary dataset.

These milestones remain targets rather than guarantees, with no VBC contract signed, Adherium’s products not approved for commercial supply in Australia, and referenced clinical data remaining preliminary.